Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a99aa8bbbad543218bc93d48c8adcbf6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a99aa8bbbad543218bc93d48c8adcbf6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a99aa8bbbad543218bc93d48c8adcbf62021-11-30T17:03:34ZNovel therapeutic strategies for patients with metastatic triple-negative breast cancer1815-14341815-144210.26442/18151434.2020.4.200495https://doaj.org/article/a99aa8bbbad543218bc93d48c8adcbf62021-02-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/61149/44238https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and tumors that require targeted or immunotherapy for the best treatment outcomes. Such subtype features make it difficult to develop a single treatment strategy for all patients. Current perceptions of resistance mechanisms and molecular drivers progression have increased therapeutic opportunities for metastatic TNBC (mTNBC). For example, in the last few years, checkpoint inhibitors and PARP inhibitors have entered into clinical practice in the Russian Federation. This review presents clinical trial data, as well as an algorithm for choosing therapy for patients with TNBC, based on the results of recent clinical studies. The review focuses mainly on drugs registered at the territory of the Russian Federation, that allows to apply these options in everyday clinical practice. Promising directions therapy of mTNBC not registered at the territory of the Russian Federation yet will be showed in a separate review in the next issue in the Journal of Modern Oncology.Inna P. GanshinaOlga O. GordeevaMariam Sh. ManukianIP Habib O.N.articletriple negative breast cancerchemotherapyantiangiogenic therapyimmunotherapyparp inhibitorsdrug therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 4, Pp 60-65 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
triple negative breast cancer chemotherapy antiangiogenic therapy immunotherapy parp inhibitors drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
triple negative breast cancer chemotherapy antiangiogenic therapy immunotherapy parp inhibitors drug therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Inna P. Ganshina Olga O. Gordeeva Mariam Sh. Manukian Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| description |
Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and tumors that require targeted or immunotherapy for the best treatment outcomes. Such subtype features make it difficult to develop a single treatment strategy for all patients. Current perceptions of resistance mechanisms and molecular drivers progression have increased therapeutic opportunities for metastatic TNBC (mTNBC). For example, in the last few years, checkpoint inhibitors and PARP inhibitors have entered into clinical practice in the Russian Federation. This review presents clinical trial data, as well as an algorithm for choosing therapy for patients with TNBC, based on the results of recent clinical studies. The review focuses mainly on drugs registered at the territory of the Russian Federation, that allows to apply these options in everyday clinical practice. Promising directions therapy of mTNBC not registered at the territory of the Russian Federation yet will be showed in a separate review in the next issue in the Journal of Modern Oncology. |
| format |
article |
| author |
Inna P. Ganshina Olga O. Gordeeva Mariam Sh. Manukian |
| author_facet |
Inna P. Ganshina Olga O. Gordeeva Mariam Sh. Manukian |
| author_sort |
Inna P. Ganshina |
| title |
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| title_short |
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| title_full |
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| title_fullStr |
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| title_full_unstemmed |
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| title_sort |
novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/a99aa8bbbad543218bc93d48c8adcbf6 |
| work_keys_str_mv |
AT innapganshina noveltherapeuticstrategiesforpatientswithmetastatictriplenegativebreastcancer AT olgaogordeeva noveltherapeuticstrategiesforpatientswithmetastatictriplenegativebreastcancer AT mariamshmanukian noveltherapeuticstrategiesforpatientswithmetastatictriplenegativebreastcancer |
| _version_ |
1718406400262012928 |